The MUC1-Targeted Silica Nanocarrier (MPPM)
Science and Technology · Friday, 5 June 2026
Innovative nanomedicine developed for targeted breast cancer treatment.
Quick highlights
- Targets breast cancer cells with precision.
- Minimizes systemic toxicity.
- Developed by Agharkar Research Institute.
Context
Developed by Indian scientists for breast cancer therapy.
Key Facts
Utilizes biodegradable silica nanoparticles.
Significance
Offers a safer alternative to traditional chemotherapy.
Challenges / Way Forward
Need for clinical trials to validate efficacy.
Exam Angle
Relevant for GS Paper III on health and technology.
Remember this
- MPPM targets breast cancer cells.
- Developed by Agharkar Research Institute.
- Minimizes side effects of treatment.
More from Friday, 5 June 2026
- University of Liverpool Campus in Bengaluru
- The India–UK Critical Minerals Global Supply Chain Observatory
- India’s First Flex-Fuel Passenger Vehicle
- The Price Stabilization Fund for Scheduled Indian Airlines
- The First Sea Shipment of Botanical-Infused Millets
- The Immigration and Foreigners (Amendment) Rules, 2026
- The MAVEN Mars Mission
- Exoplanet WASP-94A b
- Venezuela